We provide you with 20 years of free, institutional-grade data for ELYM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ELYM. Explore the full financial landscape of ELYM stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2024-05-15 | 1768446 | ELYM | 10-Q | Url |
| 2024-03-28 | 1768446 | ELYM | 10-K | Url |
| 2023-11-14 | 1768446 | ELYM | 10-Q | Url |
| 2023-08-10 | 1768446 | ELYM | 10-Q | Url |
| 2023-05-11 | 1768446 | ELYM | 10-Q | Url |
| 2023-03-06 | 1768446 | ELYM | 10-K | Url |
| 2022-11-14 | 1768446 | ELYM | 10-Q | Url |
| 2022-08-15 | 1768446 | ELYM | 10-Q | Url |
| 2022-05-16 | 1768446 | ELYM | 10-Q | Url |
| 2022-03-07 | 1768446 | ELYM | 10-K | Url |
| 2021-11-08 | 1768446 | ELYM | 10-Q | Url |
| 2021-09-13 | 1768446 | ELYM | 10-Q | Url |
| 2021-07-16 | 1768446 | ELYM | S-1 | Url |
Eliem Therapeutics, Inc(NASDAQ:ELYM) 
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The compan...
Website: http://www.eliemtx.com
Founded: 2018
CEO: Bob Azelby
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about ELYM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.